CAS: 130161-46-5 - 2-Phenylpyrimidine-5-carboxaldehyde
Formula:C11H8N2O
InChI:InChI=1/C11H8N2O/c14-8-9-6-12-11(13-7-9)10-4-2-1-3-5-10/h1-8H
- Synonyms:
- Asischem A03458
- Chembrdg-Bb 4010266
- 2-Phenyl-Pyrimidine-5-Carbaldehyde
- 2-Phenylpyrimidine-5-carboxaldehyde 97%
- 2-Phenyl-5-pyrimidinecarboxaldehye
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | 5-Pyrimidinecarboxaldehyde, 2-phenyl- REF: IN-DA000U2HCAS: 130161-46-5 | 98% | To inquire | Fri 29 Nov 24 |
 | 2-Phenylpyrimidine-5-carboxaldehyde REF: 54-OR14934CAS: 130161-46-5 | 97% | 116.00 €~267.00 € | Thu 05 Dec 24 |
 | 2-Phenylpyrimidine-5-carbaldehyde REF: 3D-FP147444CAS: 130161-46-5 | Min. 95% | To inquire | Thu 09 Jan 25 |
 | 2-Phenyl-pyrimidine-5-carbaldehyde REF: 10-F059021CAS: 130161-46-5 | 95.0% | - - - | Discontinued product |
5-Pyrimidinecarboxaldehyde, 2-phenyl-
CAS:130161-46-5
Formula:
C11H8N2O
Purity:
98%
Color and Shape:
Solid
Molecular weight:
184.1940
Ref: IN-DA000U2H
| 1g | 229.00 € | ||
| 250mg | 121.00 € |
Estimated delivery in United States, on Friday 29 Nov 2024
2-Phenylpyrimidine-5-carboxaldehyde
CAS:130161-46-5
Purity:
97%
Color and Shape:
Powder
Molecular weight:
184.19g/mol
Ref: 54-OR14934
| 1g | 267.00 € | ||
| 250mg | 116.00 € |
Estimated delivery in United States, on Thursday 5 Dec 2024
2-Phenylpyrimidine-5-carbaldehyde
CAS:130161-46-5
Please enquire for more information about 2-Phenylpyrimidine-5-carbaldehyde including the price, delivery time and more detailed …
Formula:
C11H8N2O
Purity:
Min. 95%
Molecular weight:
184.19 g/mol
Ref: 3D-FP147444
| 1g | To inquire | ||
| 2g | To inquire | ||
| 100mg | To inquire | ||
| 250mg | To inquire | ||
| 500mg | To inquire |
Estimated delivery in United States, on Thursday 9 Jan 2025
Ref: 10-F059021
| 1g | Discontinued | Request information | |
| 5g | Discontinued | Request information | |
| 2.5g | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
